Avelumab Treatment in Patients With Metastatic Merkel Cell Carcinoma

New results from the phase 3 RUBY trial make the case for the use of dostarlimab in addition to chemotherapy as a standard of care for patients with recurrent endometrial cancer.

In season 3, episode 1 of Targeted Talks, Michael A. Postow, MD, discusses available targeted agents for BRAF-mutant melanoma and ongoing clinical questions about treating the disease.

Toripalimab with bevacizumab and platinum-based chemotherapy showed promising response and disease control rates in patients with refractory, recurrent and metastatic cervical cancer.

In season 2, episode 7 of Targeted Talks, Jeff Yorio, MD, and Douglas Johnson, MD, MSCI, talk about recent advances in immunotherapy for melanoma.

Carolina Frailty Index Score can effectively assess frailty status in women with ovarian cancer.

The phase 2 KGOG3046 is the first study to show survival outcomes with the dual checkpoint blockades, durvalumab and tremelimumab, combined with neoadjuvant chemotherapy for the treatment of patients with newly diagnosed advanced ovarian cancer.